Evaluation of outcomes for psychosis and epilepsy treatment delivered by primary health care workers in Nepal: a cohort study

Table 3 Functional and familial burden for psychosis

	Program (n = 48)		Control (n = 17)		ANCOVA		Full cohort T
	Mean	(SD)	Mean	(SD)	Effect size F, partial eta²	P-val*	Mean	(SD)	Effect Size Z, r	P-val**
WHODAS					0.52, 0.01	0.52			4.60, 0.57	< 0.0001
Baseline	46.1	(24.2)	37.4	(25.6)			43.8	(24.7)
end point	23.1	(20.8)	27.1	(30.9)			24.1	(23.7)
Δ score	− 23.0	(27.0)	− 10.3	(44.3)			− 19.7	(32.6)
BAS					0.29, < 0.01	0.59			6.81, 0.84	< 0.0001
Baseline	76.5	(8.0)	76.0	(8.2)			76.4	(8.0)
end point	63.3	(6.5)	62.1	(9.3)			62.9	(7.3)
Δ score	− 13.3	(8.6)	− 13.9	(11.5)			− 13.4	(9.4)
FIS: symptoms and social behavior					0.16, < 0.01	0.69			5.94, 0.74	< 0.0001
Baseline	46.5	(9.7)	41.2	(11.4)			45.1	(10.4)
end point	31.1	(9.4)	31.6	(11.0)			31.2	(9.8)
Δ Score	− 15.4	(12.3)	− 9.6	(15.8)			− 13.9	(13.4)
FIS: impact on caregiver					2.02, 0.03	0.16			5.13, 0.64	< 0.0001
Baseline	12.0	(5.9)	10.9	(6.3)			11.7	(6.0)
end point	5.9	(4.3)	7.6	(5.7)			6.3	(4.7)
Δ score	− 6.1	(6.4)	− 3.3	(7.9)			− 5.4	(6.9)

WHODAS World Health Organization Disability Assessment Schedule 2.0 Short Version, BAS burden assessment schedule, FIS Family Interview Schedule
* P-value taken from ANCOVA (analysis of covariance) for each scale comparing program vs. control scores at end point, adjusted for baseline score
** P-value from Wilcoxon Signed-Rank Test comparing baseline to end point scores (full cohort)

ISSN: 1752-4458